


Virstatin

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-127041 | | |
| CAS No.: | 88909-96-0 | | |
| Molecular Formula: | C ₁₆ H ₁₃ NO ₄ | | |
| Molecular Weight: | 283.28 | | |
| Target: | Others | | |
| Pathway: | Others | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (441.26 mM; Need ultrasonic)

| Concentration | Solvent | Mass | | |
|---------------------------|---------|-----------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| Preparing Stock Solutions | 1 mM | 3.5301 mL | 17.6504 mL | 35.3008 mL |
| | 5 mM | 0.7060 mL | 3.5301 mL | 7.0602 mL |
| | 10 mM | 0.3530 mL | 1.7650 mL | 3.5301 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Virstatin inhibits the pili system synthesis and prevents *A. baumannii* biofilm formation. Virstatin also inhibits dimerization of the transcriptional activator ToxT^{[1][2]}.

IC₅₀ & Target

ToxT^[1]

REFERENCES

[1]. Nait Chabane Y, et al. Virstatin inhibits biofilm formation and motility of *Acinetobacter baumannii*. BMC Microbiol. 2014 Mar 12;14:62.

[2]. Shakhnovich EA, et al. Virstatin inhibits dimerization of the transcriptional activator ToxT. Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2372-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA